Contents
pdf Download PDF pdf Download XML
102 Views
58 Downloads
Share this article
Research Article | Volume 7 Issue 1 (None, 2013) | Pages 5 - 9
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris
 ,
 ,
 ,
 ,
 ,
Under a Creative Commons license
Open Access
PMID : PMC3622507
Received
Nov. 3, 2012
Published
March 30, 2013
Abstract

Background:Pityriasis rubra pilaris is a rare, chronic erythematous squamous disorder of unknown etiology. The disease is characterized initially by small follicular papules that coalesce into yellowish pink scaly plaques, palmoplantar keratoderma, diffuse furfuraceous scale of the scalp, and frequent progression to exfoliative erythroderma. Generally it is difficult to discern pityriasis rubra pilaris from other skin conditions but key-clinical features help in the diagnosis such as "islands" of spared skin within generalized erythroderma, follicular keratotic plugs, and an orange hue of the involved skin. Treatment options include topical vitamin D analogues, keratolytics, systemic acitretin, methotrexate, cyclosporine, azathioprine, fumaric acid esters, phototherapy, and anti-TNFα agents. Cases, of pityriasis rubra pilaris, successfully treated with a short-course ustekinumab therapy, have been reported.Main observations:We report a 31-year-old man with pityriasis rubra pilaris, refractory to conventional treatments, successfully treated with ustekinumab monotherapy for over 64 weeks.After failing conventional systemic agents (cyclosporine, aciretin and methotrexate), ustekinumab 45 mg has been prescribed, with the same dosing regimen as in psoriasis. The patient improved dramatically within 4 weeks of the first injection, with markedly less erythema and pruritus. Long-term control of the disease of the disease was achieved (64 weeks of treatment).Conclusion:We report this case in order to show the striking and rapid efficacy of ustekinumab in reducing the signs and symptoms of the disease. Complete remission was achieved after the third injection, but also a long-term control of the disease. The therapy was well-tolerated in our patient and no adverse events occurred.

Keywords
Recommended Articles
Case Report
Concurrent Lepra Reactions; Type 1 and Type 2 in a young male patient with borderline leprosy: Clinical and Histopathological correlation
...
Published: 02/09/2025
Original Article
Comparative Evaluation of Intralesional Corticosteroid Injection and Surgical Excision in Hypertrophic Scar Treatment
...
Published: 04/06/2022
Research Article
Efficacy of supra bioavailable itraconazole and conventional itraconazole at different dosing regimens in glabrous tinea infection
Published: 02/02/2024
Research Article
Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis
Published: 19/12/2010
© Copyright Spejalisci Dermatolodzy